Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T cell lymphoma

Full text
Author(s):
de Padua Covas Lage, Luis Alberto [1] ; Hamasaki, Debora Toshie [1] ; Moreira, Frederico Rafael [2] ; Rocha, Vanderson [1, 3, 4] ; Nogueira Zerbini, Maria Claudia [5] ; Pereira, Juliana [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Fac Med, Dept Hematol Hemotherapy & Cell Therapy, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Med, Stat Dept Hematol Hemotherapy & Cell Therapy, Sao Paulo, SP - Brazil
[3] Fundacao Prosangue, Sao Paulo, SP - Brazil
[4] Univ Oxford, Churchill Hosp, Oxford - England
[5] Univ Sao Paulo, Dept Pathol, Fac Med, Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: ANNALS OF HEMATOLOGY; v. 98, n. 9, p. 2097-2102, SEP 2019.
Web of Science Citations: 0
Abstract

Nodal peripheral T cell lymphomas (nPTCL) present aggressive clinical course, and its heterogeneous nature and poor prognosis with current therapeutic strategies make it a target for the development of new prognostic markers. Thus, we investigated tumor-associated macrophages (TAM) according to the number of cells expressing CD68 in biopsies and the absolute monocyte count (AMC) in peripheral blood of 87 patients with nPTCL. The median overall survival (OS) was 3 years (95% CI 1.3-8.4 years) and estimate 5 years OS of 43.3% (95% CI 32.5-53.7%). The median progression-free survival (PFS) was 1.5 years (95% CI 0.8-2.6 years) with estimate 5 years PFS of 29.2% (95% CI 19.7-39.3%). The cutoff for AMC was 1.5 x 10(9)/L and the median OS for patients with AMC >= 1.5 x 10(9)/L was 0.83 years versus 3.7 years for those with AMC < 1.5 x 10(9)/L (HR 2.32, 95% CI 1.03-5.22, p = 0.035). The median PFS for patients with AMC >= 1.5 x 10(9)/L was 0.50 years versus 1.5 years for those with AMC < 1.5 x 10(9)/L (HR 2.25, 95% CI 1.05-4.78, p = 0.031). CD68 was evaluated in 26/87 (29.8%) patients with a median expression of 34% and positivity cutoff of 43%. CD68 expression was not associated with OS or PFS either with AMC values. Our findings suggest that the AMC of >= 1.5 x 10(9)/L at diagnosis in peripheral blood is associated with poor prognosis in nPTCL. Further investigations in a larger cohort are required to better validate our results. (AU)

FAPESP's process: 12/50495-3 - Analysis of gene expression profile of cell proliferation and inflammatory response and the pattern of methylation of tumor suppressor genes p16INK4A and p15INK4b and its implications in the prognosis of peripheral T-cell lymphomas
Grantee:Juliana Pereira
Support Opportunities: Regular Research Grants